证券代码：002950 证券简称：奥美医疗 公告编号：2025-046 奥美医疗用品股份有限公司 注：表中部分合计数与明细数直接相加之和在尾数上如有差异，系因四舍五入造成。 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）近日接到控股股东、实际 控制人之一崔金海先生的函告，获悉崔金海先生持有的本公司部分股份办理了 质押业务，具体事项如下： | 是否为控股 | 股东或第一 | 本次质押股 | 占其所持股 | 占公司总股 | 是否为限售 | 是否为补充 | 质押开始日 | 质押到期日 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 质权人 | 用途 | 大股东及其 | 数（股） | 份比例（%） | 本比例（%） | 股 | 质押 | 期 | 期 | | | | | | | 一致行动人 | | ...

Core Viewpoint - The company is facing challenges in maintaining its market value despite strong operational performance and growth, with significant concerns raised by investors regarding its stock price and market positioning compared to competitors [2][4]. Company Performance - As of September 22, 2025, the company's stock price closed at 9.47 yuan, down 0.73%, with a trading volume of 40,400 shares and a turnover of 38.26 million yuan [1]. - The company has been compared unfavorably to competitors, with its market capitalization significantly lower than that of peers like Zhend Medical and Sturdy Medical, which have market values approximately 2 to 5 times greater [4]. M&A Strategy - The company has indicated that its future merger and acquisition (M&A) focus will be on the health industry, emphasizing the importance of synergy and industry integration [2][3]. - The management has acknowledged the high risks associated with M&A activities and has adopted a cautious approach towards potential acquisitions [2]. Market Sentiment - Investor sentiment is currently negative, with concerns about the company's declining stock price despite its strong performance and generous dividend distribution over the years [2][4]. - On September 22, 2025, there was a net outflow of 1.19 million yuan from institutional investors, while retail investors contributed a net inflow of 6.11 million yuan [4].

Core Viewpoint - The company, Aomei Medical, has denied rumors regarding plans for asset restructuring involving the injection of AI chips and humanoid robots [1] Group 1 - An investor inquired about the authenticity of rumors related to Aomei Medical's potential asset restructuring [1] - Aomei Medical confirmed that there are no such plans in place [1]

Group 1 - The core point of the article is that Aomei Medical announced a share buyback program, having repurchased a total of 1,987,400 shares as of August 31, 2025, which represents 0.3138% of the company's total share capital [1]

Group 1 - The company approved a share repurchase plan on January 20, 2025, allowing for the repurchase of shares using its own funds and a special loan for share repurchase, with a maximum price of RMB 11.00 per share and a total repurchase amount between RMB 50 million and RMB 100 million [1] - The implementation period for the share repurchase is set for 12 months from the date of board approval [1] - The company will disclose the details of the repurchase plan through designated information disclosure media [1] Group 2 - As of August 31, 2025, the company has repurchased a total of 1,987,400 shares, accounting for 0.3138% of the total share capital, with a maximum transaction price of RMB 9.26 per share and a minimum of RMB 8.33 per share, totaling RMB 18,001,207.00 spent [2] - The implementation of the repurchase plan is consistent with the initial proposal, and the company will continue to execute the plan based on market conditions [3]

Core Viewpoint - Aomei Medical (002950.SZ) has announced a share buyback program, indicating a strategic move to enhance shareholder value through repurchasing shares in the market [1] Summary by Categories Share Buyback Details - The company has repurchased a total of 1.9874 million shares, which represents 0.3138% of its total share capital [1] - The highest transaction price during the buyback was 9.26 yuan per share, while the lowest was 8.33 yuan per share [1] - The total amount spent on the buyback was 18.0012 million yuan, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - The company, Aomei Medical (002950.SZ), announced a share buyback program, having repurchased a total of 1.9874 million shares as of August 31, 2025, which represents 0.3138% of its total share capital [1] - The highest transaction price during the buyback was 9.26 yuan per share, while the lowest was 8.33 yuan per share [1] - The total amount spent on the share buyback was 18.0012 million yuan, excluding stamp duty and transaction commissions [1]

证券代码：002950 证券简称：奥美医疗 公告编号：2025-045 奥美医疗用品股份有限公司 截至目前，本次回购实施情况与回购股份方案不存在差异。公司后续将根据市场情况 在回购期限内实施本次回购计划，并按照相关法律法规的规定及时履行信息披露义务。敬 请广大投资者关注后续公告，并注意投资风险。 特此公告。 关于股份回购进展的公告 奥美医疗用品股份有限公司 董事会 2025 年 9 月 4 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）董事会于 2025 年 1 月 20 日召开第 三届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议 案》，同意公司以自有资金及股票回购专项贷款资金通过集中竞价交易方式回购公司股份， 用于股权激励或员工持股计划。本次回购价格不超过人民币 11.00 元/股（含），回购股份 的资金总额不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含），具体回购 资金总额以实际使用的资金总额为准。回购股份的实施期限为自公司董事会审议通过本次 回购方 ...

Market Overview - On September 3, the medical device sector declined by 0.57%, with Huqiang Technology leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Top Performers - Sino Medical (688108) saw a significant increase of 12.67%, closing at 36.28 with a trading volume of 750,100 shares and a transaction value of 2.57 billion [1] - Other notable gainers included: - Sanyou Medical (688085) up 7.76% to 25.70 [1] - Kangtuo Medical (688314) up 5.59% to 38.36 [1] - Rejing Bio (688068) up 5.07% to 196.26 [1] - New Industry (300832) up 4.08% to 64.82 [1] Underperformers - Huqiang Technology (688151) experienced the largest decline of 8.44%, closing at 21.48 with a trading volume of 73,900 shares and a transaction value of 164 million [2] - Other significant decliners included: - Jimin Health (603222) down 8.16% to 10.47 [2] - Aomei Medical (002950) down 4.70% to 9.73 [2] - Boxin Bio (836504) down 4.53% to 28.68 [2] Capital Flow - The medical device sector saw a net outflow of 271 million from institutional investors and 266 million from speculative funds, while retail investors contributed a net inflow of 537 million [2][3] - Notable capital flows included: - Sino Medical with a net inflow of 215 million from institutional investors [3] - Huqiang Technology with a net outflow of 1.37 billion from speculative funds [3] - Huatai Medical (688617) had a net inflow of 107 million from institutional investors [3]

Market Performance - The medical device sector increased by 1.87% on September 1, with Yirui Biological leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Medical Device Sector - Yirui Biological (300942) closed at 13.82, up 13.56% with a trading volume of 263,400 shares and a transaction value of 350 million [1] - Jimin Health (603222) closed at 12.67, up 9.98% with a trading volume of 1,050,500 shares [1] - Hualan Biological (301093) closed at 37.16, up 9.55% with a trading volume of 123,900 shares [1] - Huatai Medical (688617) closed at 305.49, up 7.43% with a trading volume of 30,100 shares [1] - United Imaging Healthcare (688271) closed at 152.10, up 7.26% with a trading volume of 147,200 shares [1] Top Losers in Medical Device Sector - Toukeng Life (300642) closed at 28.50, down 7.71% with a trading volume of 234,300 shares [2] - Blue Sail Medical (002382) closed at 5.99, down 3.07% with a trading volume of 288,400 shares [2] - Wuzhou Medical (301234) closed at 43.30, down 2.48% with a trading volume of 20,800 shares [2] Capital Flow Analysis - The medical device sector saw a net inflow of 68.08 million from institutional investors, while retail investors contributed a net inflow of 14.9 million [2] - The sector experienced a net outflow of 217 million from speculative funds [2] Individual Stock Capital Flow - Mindray Medical (300760) had a net inflow of 90.24 million from institutional investors, while it faced a net outflow of 128 million from speculative funds [3] - United Imaging Healthcare (688271) saw a net inflow of 87.93 million from institutional investors, with a net outflow of 130 million from speculative funds [3] - Jimin Health (603222) experienced a net inflow of 79.82 million from institutional investors, but a net outflow of 49.23 million from speculative funds [3]